Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia

[1]  G. Chenevix-Trench,et al.  Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia , 2021, Haematologica.

[2]  W. Tissing,et al.  Parental functioning during maintenance treatment for childhood acute lymphoblastic leukemia: Effects of treatment intensity and dexamethasone pulses , 2020, Pediatric blood & cancer.

[3]  S. MacGregor,et al.  Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children , 2020, Cancers.

[4]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[5]  M. Loh,et al.  Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Schmiegelow,et al.  Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Michel,et al.  A systematic review on the use of the emotion thermometer in individuals diagnosed with cancer , 2019, Psycho-oncology.

[8]  Paul A. Harris,et al.  The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.

[9]  G. Chenevix-Trench,et al.  Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia. , 2019, Thrombosis research.

[10]  R. Pieters,et al.  Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study , 2018, Blood.

[11]  Julie M Gastier-Foster,et al.  Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Logan,et al.  Effectiveness of nonpharmacological interventions to reduce procedural anxiety in children and adolescents undergoing treatment for cancer: A systematic review and meta‐analysis , 2018, Psycho-oncology.

[13]  Lyn M. Balsamo,et al.  Longitudinal analysis of quality‐of‐life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial , 2018, Cancer.

[14]  M. Grootenhuis,et al.  Health-related quality of life of survivors of childhood acute lymphoblastic leukemia: a systematic review , 2018, Quality of Life Research.

[15]  M. Grootenhuis,et al.  Health‐related quality of life of children on treatment for acute lymphoblastic leukemia: A systematic review , 2017, Pediatric blood & cancer.

[16]  G. Buck,et al.  Prospective evaluation of quality of life in children treated in UKALL 2003 for acute lymphoblastic leukaemia: A cohort study , 2017, Pediatric blood & cancer.

[17]  K. Schmiegelow,et al.  Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy , 2017, F1000Research.

[18]  K. Schmiegelow,et al.  Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol , 2017, Leukemia.

[19]  M. Loh,et al.  Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Loh,et al.  A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children’s Oncology Group Study AALL08P1 , 2016, Journal of pediatric hematology/oncology.

[21]  L. Silverman,et al.  Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. , 2016, The Lancet. Oncology.

[22]  Xiaomin Lu,et al.  Anxiety, pain, and nausea during the treatment of standard‐risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group , 2016, Cancer.

[23]  N. Hijiya,et al.  Rechallenging With Intrathecal Methotrexate After Developing Subacute Neurotoxicity in Children With Hematologic Malignancies , 2016, Pediatric blood & cancer.

[24]  Lyn M. Balsamo,et al.  Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331 , 2016, International journal of cancer.

[25]  J. Downing,et al.  Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Jie J. Zheng,et al.  Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. , 2015, JAMA.

[27]  S. Gupta,et al.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 2014, Kathmandu University medical journal.

[28]  R. Pieters,et al.  Determinants of quality of life during induction therapy in pediatric acute lymphoblastic leukemia , 2014, Supportive Care in Cancer.

[29]  M. Hudson,et al.  Survivors of childhood and adolescent cancer: life-long risks and responsibilities , 2013, Nature Reviews Cancer.

[30]  Lynette M. Smith,et al.  Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's Oncology Group , 2013, British journal of haematology.

[31]  R. Wade,et al.  Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003 , 2013, British journal of haematology.

[32]  C. Pui,et al.  A 50-year journey to cure childhood acute lymphoblastic leukemia. , 2013, Seminars in hematology.

[33]  M. Valsecchi,et al.  Screening for Coagulopathy and Identification of Children With Acute Lymphoblastic Leukemia at a Higher Risk of Symptomatic Venous Thrombosis: An AIEOP Experience , 2013, Journal of pediatric hematology/oncology.

[34]  R. Pieters,et al.  High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation , 2013, Leukemia.

[35]  R. Gelber,et al.  Health‐related quality of life among children with acute lymphoblastic leukemia , 2012, Pediatric blood & cancer.

[36]  J. Gastier-Foster,et al.  Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2011, Blood.

[37]  N. Winick,et al.  Quality of life during active treatment for pediatric acute lymphoblastic leukemia , 2011, International journal of cancer.

[38]  D. Neuberg,et al.  The frequency and management of asparaginase‐related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana‐Farber Cancer Institute consortium protocols , 2011, British journal of haematology.

[39]  W. Landier,et al.  Use of complementary and alternative medical interventions for the management of procedure-related pain, anxiety, and distress in pediatric oncology: an integrative review. , 2010, Journal of pediatric nursing.

[40]  M. Relling,et al.  Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. , 2010, Blood.

[41]  V. Poggi,et al.  Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution , 2010, Leukemia & lymphoma.

[42]  J. V. van Dongen,et al.  Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. , 2010, Blood.

[43]  A. Mitchell,et al.  Can the Distress Thermometer be improved by additional mood domains? Part I. Initial validation of the Emotion Thermometers tool , 2010, Psycho-oncology.

[44]  A. Mitchell,et al.  Can the Distress Thermometer be improved by additional mood domains? Part II. What is the optimal combination of Emotion Thermometers? , 2010, Psycho-oncology.

[45]  N. Heerema,et al.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. Haber,et al.  Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia , 2009, British journal of haematology.

[47]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[48]  A. Wiener,et al.  Health-related Quality of Life (HRQL) in ALL-patients Treated with Chemotherapy only – A Report from the Late Effects Surveillance System in Germany , 2009, Klinische Padiatrie.

[49]  C. McAuley,et al.  Quality of life in children with acute lymphoblastic leukaemia: a systematic review. , 2009, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[50]  L. Thabane,et al.  Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer , 2008, Pediatric blood & cancer.

[51]  N. Heerema,et al.  Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2008, Blood.

[52]  Christian Urban,et al.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. , 2007, Blood.

[53]  D. Flockhart,et al.  Predicting asparaginase‐associated pancreatitis , 2007, Pediatric blood & cancer.

[54]  R. Pieters,et al.  A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial , 2007, The Lancet.

[55]  L. Iacoviello,et al.  Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. , 2006, Blood.

[56]  N. Heerema,et al.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. , 2006, Blood.

[57]  C. Stride,et al.  HRQOL implications of treatment with dexamethasone for children with acute lymphoblastic leukemia (ALL) , 2006, Pediatric blood & cancer.

[58]  J. Varni,et al.  Parent proxy–reported health‐related quality of life and fatigue in pediatric patients diagnosed with brain tumors and acute lymphoblastic leukemia , 2004, Cancer.

[59]  D. Feeny,et al.  The Health Utilities Index (HUI®): concepts, measurement properties and applications , 2003, Health and quality of life outcomes.

[60]  J. Varni,et al.  The PedsQL™ in pediatric cancer , 2002, Cancer.

[61]  R. Gelber,et al.  Bony morbidity in children treated for acute lymphoblastic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  O. Alvarez,et al.  Pegaspargase-induced pancreatitis. , 2000, Medical and pediatric oncology.

[63]  C. Pui,et al.  Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia , 1998, Leukemia.

[64]  M. Valsecchi,et al.  Open Ac ce s s Correspondence : Osteonecrosis in childhood acute lymphoblastic leukemia : a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology ( AIEOP ) , 2018 .

[65]  K. Schmiegelow,et al.  Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial. , 2014, European journal of cancer.

[66]  R. Arceci.  Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group , 2009 .

[67]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..